e255e8fa-b1c7-42bf-9934-4ea44bed860f
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 50
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.670
- MYC_TARGETS_V1+0.550
- E2F_TARGETS+0.520
- G2M_CHECKPOINT+0.520
- MTORC1_SIGNALING+0.380
- OXIDATIVE_PHOSPHORYLATION+0.380
- UNFOLDED_PROTEIN_RESPONSE+0.360
- TNFA_SIGNALING_VIA_NFKB+0.330
- DNA_REPAIR+0.320
- GLYCOLYSIS+0.280
Top 10 suppressed
- BILE_ACID_METABOLISM-0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- HEDGEHOG_SIGNALING-0.270
- INTERFERON_GAMMA_RESPONSE-0.270
- ALLOGRAFT_REJECTION-0.260
- INTERFERON_ALPHA_RESPONSE-0.260
- COAGULATION-0.220
- MYOGENESIS-0.220
- PROTEIN_SECRETION-0.220
- COMPLEMENT-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-77-8144-01A-11R-2247-07 | — | cohortSQ1 | 0.828 |
| 2 | MDT-AP-0366 | Med | Medulloblastoma | 0.821 |
| 3 | SRR8613795 | — | E | 0.811 |
| 4 | TCGA-56-A5DR-01A-11R-A27Q-07 | — | cohortSQ1 | 0.806 |
| 5 | TCGA-MF-A522-01A-11R-A262-07 | — | cohortSQ2 | 0.802 |
| 6 | SRR8518329 | — | E | 0.799 |
| 7 | TCGA-56-7222-01A-11R-2045-07 | — | cohortSQ1 | 0.798 |
| 8 | TCGA-BB-A5HY-01A-11R-A28V-07 | — | — | 0.795 |
| 9 | TCGA-85-8277-01A-11R-2296-07 | — | cohortSQ2 | 0.787 |
| 10 | AUR-AE6Y-TTM1-A-1-1-R-A742-41 | — | E | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.670 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.270 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.150 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |